buspirone BUSPAR

Class: 5HT1A Agonist
FDA Indications: GAD
Off-Label Use: Cannabis Dependence, Smoking Cessation, Hypoactive Sexual Desire Disorder, ADHD, Treatment Resistant Depression
Forms: 5, 10, 15, 30mg tablet
Dose Range: 20-60 mg/day
Starting: 15 mg bid, increase by 5 mg increments until desired efficacy achieved
Stopping: Taper generally not necessary

NAMI drug fact sheet

Serious Side Effects: Infrequent syncope, hypotension and hypertension. Rare cardiovascular adverse events include CVAs, CHF, MI, CMP, and bradycardia
Side Effects: xerostomia, constipation, nausea, weight loss, anorexia, myalgia, insomnia, dizziness, headache, agitation, anxiety, tremor, tremor, hyperhidrosis, tinnitus
1° MOA: Preferential full agonist of presynaptic 5-HT1A receptors, which are inhibitory autoreceptors
2° MOA: Partial agonist of postsynaptic 5-HT1A receptors
t½: 2.8° TMAX:
Substrate of: 3A4
Inhibits: ∅ ; Induces:
Active Metabolites: 1-PP
  • - patients who are benzodiazepine naive respond better than those who are switched from a benzodiazepine
  • - ∅ sexual dysfunction; ∅ weight gain
  • - ∅ dependence or withdrawal
  • - may reduce sexual dysfunction associated with GAD and/or with SSRIs
Special Populations

Category B—Although no drug-induced congenital malformations have been observed after 1st-trimester exposure to buspirone, the data are too limited to assess the safety of the drug in human pregnancy.

Because of the potential for CNS impairment in a nursing infant, maternal use of the drug, especially for prolonged periods, should be undertaken cautiously, if at all.

There were no effects of age on the pharmacokinetics of buspirone

Caution in severe impairment

Caution in severe impairment


Developed & Designed by Kevin M. Nasky, D.O. • Built with Bootstrap, PHP & MySQL • Hosted by SiteGround
Last updated February 29 2024 20:54:18. Disclaimer: This website does not provide medical advice, nor is it a substitute for clinical judgment.